Technical / white paper
02-Jul-2009 -
The formation of aggregates in biopharmaceuticals such as monoclonal antibodies (MAbs), represents a severe problem, which has also been addressed by FDA authorities recently. Particularly their potential to trigger or enhance undesirable immune responses may cause adverse clinical effects or...